This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Affordable Breakout Stocks for Stunning Returns
by Nitish Marwah
Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.
Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session
by Zacks Equity Research
Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Avenue Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avenue Therapeutics
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
by Zacks Equity Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
Flexion (FLXN) Soars: Stock Adds 6.6% in Session
by Zacks Equity Research
Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide
by Zacks Equity Research
Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide
Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings
by Zacks Equity Research
Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings
How Avenue (ATXI) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pick These 5 Stocks With Superb Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
4 Breakout Stocks for Impressive Returns
by Nitish Marwah
The logic behind the breakout strategy for stock selection is to identify stocks are trading within a narrow band.
Technology on Solid Footing: 5 Stocks With More Room to Run
by Sanghamitra Saha
Tech rally is here to stay on solid fundamentals. Bet on stocks that are yet to reclaim their 52-week high levels despite the recent uptrend.
Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Top Ranked Momentum Stocks to Buy for April 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick
by Zacks Equity Research
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
5 Top Small-Cap Stocks Braving Coronavirus Bloodbath
by Nalak Das
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).